EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

These results suggest that EGFR TKI therapy is effective in patients with L861Q/G719X/Del-19 + L858R/Del-19 or L858R + other mutations; less effective in patients with 20ins/Del-19 or L858R + T790 M.